| fosaprepitant / Generic mfg. |
ChiCTR2000040681: Comparative study of efficacy of fosaprepitant and aprepitant in preventing chemotherapeutic vomiting in children receiving moderate and high emetogenic chemotherapeutic agents |
|
|
| Completed | 4 | 120 | | Children recruited to arm-A received intravenous ondansetron plus dexamethasone followed by fosaprepitant infusion. Children recruited to arm-B received the same drugs as those given to children in arm-A, except that fosaprepitant was substituted with aprepitant. Ondansetron and dexamethasone were continued for 48 hours after& | Shanghai Children's Medical Center; Shanghai Children's Medical Center, Project of Shanghai Children's Medical Center | Vomiting after chemotherapy | | | | |
ChiCTR2000039884: Effect and Safety of Fosaprepitant Dimeglumine for the Management of Chemotherapy-Induced Nausea and Vomiting: an Observational Registry Study |
|
|
| Recruiting | 4 | 3000 | | Nil | Shandong Provincial Qianfoshan Hospital; Level of the institution：, Chia-tai Tianqing Pharmaceutical Co., Ltd | Chemotherapy-induced Nausea and Vomiting | | | | |
ChiCTR2100042665: A randomised controlled trial about the antiemetic effect of prolonged administration of fosaprepitant for lung cancer patients receiving 3 days cisplatin-based chemotherapy |
|
|
| Recruiting | 4 | 204 | | fosaprepitant 150mg IV, chemotherapy day1, 3 ;fosaprepitant 150mg IV, chemotherapy day1 | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Zheng Da Tian Qing Pharmaceutical Group Co. Ltd | lung cancer | | | | |
ChiCTR2200060890: A multicenter, randomized, double-blind, parallel controlled clinical trial of fosaprepitant combined with palonosetron and dexamethasone versus placebo combined with palonosetron and dexamethasone in the prevention of postoperative nausea and vomiting in patients undergoing gynecological tumor surgery |
|
|
| Not yet recruiting | 4 | 154 | | Fosaprepitant combined with palonosetron and dexamethasone; Placebo combined with palonosetron and dexamethasone | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, None | Postoperative nausea and vomiting | | | | |
ChiCTR2400088071: The Effect of Fosaprepitant on Postoperative Delirium and Sleep Quality in Elderly Gynecological Laparoscopic Surgery Patients: A Prospective Randomized Controlled Study |
|
|
| Not yet recruiting | 4 | 310 | | Intravenous infusion of 150 mg fosaprepitant for injection dissolved in 150 ml 0.9% sodium chloride injection before anesthesia induction; Intravenous infusion of 150 ml 0.9% sodium chloride injection before anesthesia induction | Obstetrics and Gynecology Hospital of Fudan University; Obstetrics and Gynecology Hospital of Fudan University, Funding for the research group | Postoperative Cognitive Dysfunction And Postoperative Sleep Disturbance | | | | |
NCT05841849: Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer |
|
|
| Not yet recruiting | 4 | 1028 | RoW | Aprepitant, Palonosetron, Fosaprepitant | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Cancer, Chemotherapy-induced Nausea and Vomiting | 07/28 | 07/29 | | |
SPARED trial, UMIN000032269: Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 4 With Combined Neurokinin-1 Receptor Antagonist, Palonosetron and Olanzapine in High- Emetogenic Chemotherapy |
|
|
| Active, not recruiting | 3 | 280 | Japan | dexamethasone - Generic mfg., palonosetron intravenous - Generic mfg., olanzapine - Generic mfg., aprepitant oral - Generic mfg., fosaprepitant - Generic mfg. | St.Marianna University School of Medicine Hospital, AMED (Japan Agency for Medical Research and Development) | Malignant solid tumor | | | | |
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study |
|
|
| Not yet recruiting | 3 | 352 | RoW | olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen | Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy | 02/21 | 03/21 | | |
A221602, NCT03578081: Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy |
|
|
| Completed | 3 | 690 | US, RoW | Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Malignant Neoplasm | 11/21 | 05/23 | | |
NCT04873284: Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients |
|
|
| Not yet recruiting | 3 | 120 | RoW | fosaprepitant, aprepitant, Granisetron plus dexamethasone | Shanghai Children's Medical Center | Chemotherapy Induced Nausea and Vomiting, Pediatric Cancer Patients | 12/21 | 12/21 | | |
NCT04912271: Granisetron Transdermal Patch for Prophylaxis of Delayed CINV |
|
|
| Not yet recruiting | 3 | 140 | NA | Granisetron transdermal patch, sancuso, Palonosetron, Aprepitant, Fosaprepitant, Dexamethasone | Fudan University | Chemotherapy-induced Nausea and Vomiting (CINV) | 06/22 | 12/23 | | |
PROFIT, NCT05509634: Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors |
|
|
| Completed | 3 | 754 | RoW | HR20013 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone | Fujian Shengdi Pharmaceutical Co., Ltd. | Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy | 06/23 | 08/23 | | |
NCT06200168: Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer |
|
|
| Recruiting | 3 | 370 | RoW | Electroacupuncture, Standard antiemetic treatment, Sham electroacupuncture | Jiuda Zhao | Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting | 10/26 | 12/26 | | |
NCT05244577: Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer |
|
|
| Recruiting | 3 | 75 | RoW | Olanzapine Tablets, Olanzapine, Placebo | Shi Yanxia | Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin | 12/23 | 03/24 | | |
| Completed | 3 | 442 | RoW | Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen, Fosaprepitant+Tropisetron+Olanzapine, Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen, Fosaprepitant+Tropisetron+Olanzapine+Dexamethasone | Henan Cancer Hospital | Chemotherapy-induced Nausea and Vomiting | 08/23 | 08/23 | | |
NCT06282211: the Efficacy and Safety of Ondansetron Oral Soluble Pellicles |
|
|
| Recruiting | 3 | 184 | RoW | Ondansetron Oral Soluble Pellicles, Aiqisu | The First Affiliated Hospital of Xinxiang Medical College | Nausea and Vomiting | 03/24 | 12/24 | | |
NCT04503668: Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients |
|
|
| Terminated | 3 | 62 | US | Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Fosaprepitant, Olanzapine, Zyprexa, Compazine | University of Michigan Rogel Cancer Center | Gynecologic Cancer | 01/24 | 03/24 | | |
NCT05564286: Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer |
|
|
| Completed | 3 | 116 | RoW | Fosaprepitant, shanqi, tropisetron, luoting, Dexamethasone, xiluoan | Shantou University Medical College | Cervical Cancer, Nasopharyngeal Cancer, Chemotherapy-induced Nausea and Vomiting, Radiation-Induced Nausea and Vomiting, Antiemetic | 07/23 | 08/23 | | |
FONDO-LOW, NCT06588413: Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan |
|
|
| Recruiting | 3 | 172 | US | Olanzapine, Zyprexa | Augusta University | Multiple Myeloma, Autologous Stem Cell Transplantation | 10/27 | 10/27 | | |
| Recruiting | 2/3 | 250 | US | Fosaprepitant 150 mg, Ondansetron 4 mg | Montefiore Medical Center | Nausea and Vomiting, Nausea, Vomiting | 05/25 | 05/25 | | |
BARF RCT, NCT06740812: Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide |
|
|
| Not yet recruiting | 2/3 | 212 | US | Fosaprepitant, Metoclopramide | Montefiore Medical Center | Nausea and Vomiting, Nausea, Vomiting | 03/26 | 03/26 | | |
NCT04508400: Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients |
|
|
| Completed | 2 | 108 | RoW | Fosaprepitant,ondansetron, dexamethasone, ondansetron, dexamethasone, placebo ondansetron with dexamethasone | Sun Yat-sen University | Pediatric Cancer | 06/23 | 06/23 | | |
ChiCTR2000035363: Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients with solid tumors receiving moderately and highly emetogenic chemotherapy: a multi-center, randomised, double-blind, parallel control phase II randomized trial. |
|
|
| Not yet recruiting | 2 | 108 | | fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients with solid tumors receiving moderately and highly emetogenic chemotherapy ;lacebo plus ondansetron with dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) with MEC/HE multi-day chemotherapy | Sun Yat-sen University Cancer center; Level of the institution：, Jiangsu Chia Tai-Tianqing Pharmaceutical co., Ltd | pediatric solid tumors | | | | |
ChiCTR2400081605: A randomized, controlled, multicenter, phase II clinical trial of the combination of Fosapitam with chemotherapy and bevacizumab in the second-line treatment of advanced colorectal cancer |
|
|
| Not yet recruiting | 2 | 82 | | Fosapitam+mFOLFOX6/FOLFIRI/CAPEOX+bevacizumab; mFOLFOX6/FOLFIRI/CAPEOX+bevacizumab | The 903rd Hospital of the Joint Logistics Support Force of the People's Liberation Army of China; The 903rd Hospital of the Joint Logistics Support Force of the People's Liberation Army of China, This is an investigator-initiated clinical trial and no fundings available | Advanced colorectal cancer | | | | |
| Completed | 1 | 9 | US | mFOLFIRINOX, Proton beam radiation | Georgetown University | Resected Pancreatic Adenocarcinoma | 05/22 | 11/23 | | |
NCT06427681: An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 40 | NA | BH006 for injection, Fosaprepitant for injection+Palonosetron hydrochloride injection, EMEND®+PALONOSETRON | Zhuhai Beihai Biotech Co., Ltd | Bioavailability | 09/24 | 12/24 | | |
NCT05230654: Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs |
|
|
| Not yet recruiting | N/A | 120 | RoW | Fosaprepitant, Placebo(normal saline) | Shanghai Children's Medical Center | Chemotherapy Induced Nausea and Vomiting Pediatric Cancer Patients | 04/22 | 05/22 | | |
ChiCTR2100043667: Repeat-dose versus single-dose fosaprepitant combined with azasetron and dexamethasone for the prevention of concurrent chemoradiotherapy-induced nausea and vomiting in patients with gynecologic cancer: single-center, randomized, parallel-controlled study |
|
|
| Recruiting | N/A | 90 | | fosaprepitantD1,D3+standard treatment ;fosaprepitantD1+standard treatment ;standard treatment | Xuzhou Central Hospital; Xuzhou Central Hospital, self-financing | gynecologic cancer | | | | |
NCT05881486: Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery |
|
|
| Not yet recruiting | N/A | 234 | NA | Ondansetron 8mg, Fosaprepitant 150 mg | Qilu Hospital of Shandong University | Postoperative Nausea and Vomiting, Anesthesia Complication, Thoracic Diseases | 06/23 | 06/23 | | |
NCT05773950: Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant as PONV Prevention |
|
|
| Enrolling by invitation | N/A | 144 | RoW | fosaprepitant, emend, normal saline, placebo | Samsung Medical Center | Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy | 03/24 | 03/24 | | |
NCT06443697: A Machine Learning Prediction Model for Delayed CIPONV |
|
|
| Completed | N/A | 1154 | RoW | No intervention | Sixth Affiliated Hospital, Sun Yat-sen University | Postoperative Nausea and Vomiting | 05/24 | 05/24 | | |
NCT05275569: Personalized Electroacupuncture Treatment for Chemotherapy-induced Nausea and Vomiting in Breast Cancer (PET) |
|
|
| Recruiting | N/A | 234 | RoW | True acupuncture + standard antiemetic treatment, Sham acupuncture + standard antiemetic treatment | Affiliated Hospital of Qinghai University | Cancer | 06/24 | 12/24 | | |
COSEFDIP, NCT05755659: Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV. |
|
|
| Recruiting | N/A | 3000 | RoW | Fosaprepitant Dimeglumine for Injection, ShanQi®️ | Xijing Hospital | Neoplasms | 10/24 | 12/24 | | |
ChiCTR2400087760: A real-world study on the safety and effectiveness of aprepitant injection and fosaprepitant dimeglumine for injection in preventing chemotherapy-related nausea and vomiting (CINV) in cancer patients |
|
|
| Not yet recruiting | N/A | 2000 | | None | Shanghai General Hospital; Shanghai General Hospital, / | Adverse reactions such as nausea and vomiting after chemotherapy | | | | |
